




RealRate

PHARMACEUTICAL 2020

Moleculin Biotech Inc.
Rank 186 of 358





RealRate

PHARMACEUTICAL 2020

Moleculin Biotech Inc.
Rank 186 of 358



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Moleculin Biotech Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 41% points above the market average of 36%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 13,484 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 3,570 |
| Liabilities, Non-Current | 276 |
| Other Assets | 11,435 |
| Other Compr. Net Income | -4.0 |
| Other Expenses | -4,092 |
| Other Liabilities | 5,818 |
| Other Net Income | 28 |
| Other Revenues | 0 |
| Property and Equipment | 316 |
| Research and Development | 11,013 |
| Selling, General and Administrative Expense | 6,312 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 25,235 |
| Liabilities | 9,664 |
| Expenses | 13,233 |
| Revenues | 0 |
| Stockholders Equity | 15,571 |
| Net Income | -13,205 |
| Comprehensive Net Income | -13,207 |
| Economic Capital Ratio | 78% |